Ticker
VCYT
Analysis
Veracyte, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to VCYT.
Veracyte, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to VCYT.
VCYT
Stock
$4.28B
Health Technology
Medical Specialties
USD
Veracyte, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO
SOUTH SAN FRANCISCO, Calif., May 15, 2026--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Review valuation context for Veracyte, Inc..
Review future growth context for Veracyte, Inc..
Review past performance context for Veracyte, Inc..
Review financial health context for Veracyte, Inc..
Review dividend context for Veracyte, Inc..
Review management context for Veracyte, Inc..
Review ownership context for Veracyte, Inc..
Review other information context for Veracyte, Inc..
Review community context for Veracyte, Inc..